Hydrochloric Acid

Hydrochloric Acid

SCHEMBL3543099

CC1(N)CCC(=O)NC1=O.[Cl-].[H+]

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 4/20 0.39
CYP19A1 P11511 12/20 0.38
CYP3A4 P08684 2/20 0.38
CYP17A1 P05093 1/20 0.38
CYP11A1 P05108 1/20 0.38
TBXAS1 P24557 1/20 0.38
PMP22 Q01453 1/20 0.38
PDE4D Q08499 1/20 0.38
PDE3A Q14432 1/20 0.38
NFKB1 P19838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL283235 0.96 CRBN (0.39) CRBNCYP19A1CYP3A4CYP17A1CYP11A1
Bromide SCHEMBL282645 0.96 CRBN (0.39) CRBNCYP19A1CYP3A4CYP17A1CYP11A1
SCHEMBL8259939 0.96 CRBN (0.41) CRBNCYP19A1CYP3A4CYP17A1CYP11A1
SCHEMBL21848668 0.96 CRBN (0.41) CRBNCYP19A1CYP3A4CYP17A1CYP11A1
SCHEMBL632775 0.96 CRBN (0.41) CRBNCYP19A1CYP3A4CYP17A1CYP11A1
Hydrochloric Acid SCHEMBL1398914 0.93 CRBN (0.40) CRBNCYP19A1CYP3A4CYP17A1CYP11A1
Bromide SCHEMBL283607 0.93 CRBN (0.40) CRBNCYP19A1CYP3A4CYP17A1CYP11A1
Bromide SCHEMBL283262 0.93 CRBN (0.40) CRBNCYP19A1CYP3A4CYP17A1CYP11A1
Hydrochloric Acid SCHEMBL18449191 0.93 CRBN (0.40) CRBNCYP19A1CYP3A4CYP17A1CYP11A1
Bromide SCHEMBL283263 0.93 CRBN (0.40) CRBNCYP19A1CYP3A4CYP17A1CYP11A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820697-B2 Compositions and method for reducing TNFα levels CELGENE CORPORATION (US) 2010-10-26 US disclosed
US-20080287496-A1 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels CELGENE CORPORATION 2008-11-20 US disclosed
US-20060030592-A1 I-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels CELGENE CORPORATION 2006-02-09 US disclosed
EP-1064277-B1 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES CELGENE CORP (US) 2005-06-15 EP disclosed
EP-1357120-A1 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines CELGENE CORPORATION (US) 2003-10-29 EP disclosed
US-20030028028-A1 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels CELGENE CORPORATION 2003-02-06 US disclosed
US-6403613-B1 ANTI-INFLAMMATORY AGENT THAT REDUCES LEVELS OF CYTOKINES (INCLUDING TUMOR NECROSIS FACTOR) CELGENE CORPORATION 2002-06-11 US disclosed
US-20010006973-A1 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS MAN HON-WAH (US) 2001-07-05 US disclosed
EP-1064277-A1 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES Gelgene Corporation (US) 2001-01-03 EP disclosed
WO-1999047512-A1 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES COLGENE CORPORATION (US) 1999-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030592-A1 I-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels IL1A, IL1B, TNF CRBN 4100/4885CYP19A1 548/4885CYP3A4 897/4885
US-20080287496-A1 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels IL1A, IL1B, TNF CRBN 4056/4885CYP19A1 498/4885CYP3A4 911/4885
US-20010006973-A1 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS TNF, IL1A, IL1B CRBN 4134/4885CYP19A1 528/4885CYP3A4 877/4885
US-20030028028-A1 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels TNF, IL1A, IL1B CRBN 4134/4885CYP19A1 528/4885CYP3A4 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.